Related by context. All words. (Click for frequent words.) 67 Advexin 66 Evoltra ® 66 Allovectin 7 66 successfully commercialize Iluvien 65 FOLOTYN ® 65 LBH# 65 telomerase inhibitor drug 65 ruxolitinib 65 ADVEXIN therapy 65 MGN# 64 ALN PCS 64 Dacogen injection 64 Phase #b/#a clinical 64 acyclovir Lauriad R 64 Entereg R 64 Entereg TM 64 GVAX R 64 LEP ETU 64 Phase #/#a trial 64 IL# PE#QQR 64 Li Fraumeni Syndrome 63 Phase IIb clinical trials 63 refractory chronic lymphocytic 63 BRIM2 63 Biologic License Application BLA 63 forodesine 63 REOLYSIN ® 63 trastuzumab DM1 T DM1 63 Cimzia TM 63 Aryplase 63 PLK1 SNALP 63 CINTREDEKIN BESUDOTOX 63 ADVEXIN 63 AzaSite Plus 63 ADVEXIN p# therapy 63 phase IIb clinical 63 MOZOBIL 63 GVAX ® 63 Proxinium TM 63 midstage clinical trials 62 NSABP C 62 PDX pralatrexate 62 RIGScan CR 62 rALLy trial 62 pain palliation 62 Panzem R NCD 62 Zemiva TM 62 Targretin capsules 62 Panzem R 62 R sorafenib tablets 62 PrevOnco ™ 62 PRECISE trial 62 BrachySil TM 62 UPLYSO 62 EGS# 62 Surfaxin LS 62 TELCYTA 62 ospemifene 62 Allovectin 7 ® 62 supplemental biologics 62 NV1FGF 62 generation purine nucleoside 62 squalamine 62 TELINTRA 62 Neo Kidney Augment 62 CRMD# 62 vidofludimus 62 peginesatide 62 ZFP Therapeutics 62 oral ridaforolimus 62 Azixa 62 Cloretazine ® 62 SinuNase TM 61 PANVAC VF 61 Glybera R 61 BR.# 61 alvimopan 61 Selective Electrochemical Tumor Ablation 61 Insegia 61 Zenvia ™ 61 Zybrestat 61 Xanafide 61 BENLYSTA ® 61 Amrubicin 61 Cloretazine R 61 Solazed TM 61 HDL Selective Delipidation 61 PREOS R 61 Civacir 61 EOquin TM 61 BLA filing 61 TKM ApoB 61 ALN TTR 61 ridaforolimus 61 EFAPROXYN 61 volociximab 61 Soliris TM eculizumab 61 Neuradiab 61 oral deforolimus 61 Curaxin CBLC# 61 sorafenib tablets 61 autoimmune indications 61 alemtuzumab MS 61 mocetinostat MGCD# 61 hoFH 61 Allovectin 7 R 61 Prestara 61 TRIOLEX HE# APOPTONE HE# 61 PrevOnco 61 Hedgehog Pathway Inhibitor 61 ponatinib 61 TYZEKA 61 tolevamer 61 Phase IIb III 61 Androxal TM 61 Cellegesic 61 JOULFERON 61 OPAXIO 60 APPRAISE 60 Canvaxin TM 60 acetonide FA 60 Omigard 60 clevidipine 60 PREOS 60 investigational antiplatelet agent 60 Ketotransdel 60 sodium thiosulfate STS 60 Azedra ™ 60 novel histone deacetylase 60 PNP inhibitor 60 EXPAREL ™ 60 Orathecin 60 evaluating satraplatin 60 oral prodrug 60 zalutumumab 60 tanespimycin 60 PI3K/Akt pathway inhibitor 60 eltrombopag 60 MAXY G# 60 trastuzumab DM1 60 celgosivir 60 Vicinium TM 60 Factor VIIa 60 TOCOSOL Paclitaxel 60 metastatic pancreatic 60 novel therapeutic antibodies 60 TNFerade TM 60 Genasense ® oblimersen 60 alvespimycin 60 synthetic retinoid 60 Onalta ™ 60 lintuzumab SGN 60 vaccines oncolytic virus 60 OvaRex ® MAb 60 sNDA submission 60 inflammatory autoimmune diseases 60 LEVADEX ™ 60 investigational therapies 60 StemEx R 60 BEMA TM Fentanyl 60 L BLP# 60 custirsen 60 Genasense ® 60 Symphony tCGM 60 OvaRex R 60 ONCONASE R 60 talactoferrin 60 orBec 60 Azedra TM 60 neratinib 60 EP #R 60 adjuvant colon cancer 60 Phase #b/#a 60 BLA submission 60 SUCCEED trial 60 INCB# [001] 60 phase IIa clinical 60 COMFORT II 60 StaphVAX R 60 OncoVEX 60 BrachySil 60 HuMax EGFr 60 ularitide 60 punctal plug 60 Azedra 60 registrational trial 60 histamine dihydrochloride 60 Vandetanib 60 YONDELIS 60 Dalbavancin 60 Trofex 60 indiplon capsules 59 Stimuvax R 59 pralatrexate 59 JAK inhibitor 59 Evoltra 59 Cleviprex TM clevidipine 59 Corlux 59 Phenoptin 59 Vectibix panitumumab 59 Zemplar Capsules 59 Zemiva ™ 59 Phase 2b kidney transplant 59 including eniluracil ADH 59 selective androgen receptor modulator 59 INTEGRILIN R eptifibatide Injection 59 delivers fluocinolone acetonide FA 59 Troxatyl 59 HuMax TAC 59 Revimmune TM 59 ixabepilone 59 fosbretabulin 59 Anturol 59 Pyridorin 59 Virulizin ® 59 Phase Ib study 59 Revimmune 59 oxymorphone ER 59 registrational 59 Chemophase 59 evaluating REVLIMID 59 RELOVAIR ™ 59 punctal plug delivery 59 Pivotal Phase III 59 ELADUR 59 demonstrated antitumor activity 59 nonclinical studies 59 Solazed 59 Personalized Immunotherapy 59 severe hypercholesterolemia 59 CONBRIZA 59 oncolytic virus therapies 59 Tectin TM 59 lumiliximab 59 OMAPRO ™ 59 humanised monoclonal antibody 59 Iluvien ® 59 rALLy clinical trial 59 CMV vaccine 59 docetaxel Taxotere R 59 MyVax R 59 FavId 59 Proxinium 59 Alimta pemetrexed 59 preclinical efficacy 59 deforolimus 59 refractory acute myeloid 59 forodesine hydrochloride 59 rheumatoid arthritis thrombocytopenia 59 ALN TTR# 59 ELACYT 59 DPX Survivac 59 novel VDA molecule 59 SUTENT ® 59 Modrenal R 59 taribavirin 59 Panzem 59 Thalomid ® 59 cetuximab Erbitux 59 Phase 1a clinical 59 CIMZIA TM certolizumab pegol 59 Exelixis compounds 59 interferon gamma 1b 59 XL# XL# XL# 59 Kosan dependence 59 Cloretazine 59 Panzem NCD 59 Cintredekin besudotox 59 Generx TM 59 JAK2 inhibitor 59 ongoing Phase 1b 59 immunotherapeutic vaccine 59 tezampanel NGX# 59 ANTEGREN 59 ONCASPAR 59 Allovectin 7 r 59 lintuzumab 59 Exherin 59 Phase 1b clinical trials 59 paclitaxel poliglumex 59 GEM OS2 59 adjuvant GIST 59 CTAP# Capsules 59 Augment Injectable 59 axitinib 59 docetaxel Taxotere ® 58 LibiGel ® 58 XL# anticancer compounds 58 PEG PAL 58 tafamidis 58 PEG SN# 58 iii GTx 58 kidney urologic 58 cintredekin besudotox 58 Phase Ib IIa 58 TBC# 58 LymphoStat B TM 58 Phase IIIb clinical 58 liprotamase 58 Campath alemtuzumab 58 CYT# potent vascular disrupting 58 Proellex TM 58 Urocidin 58 ROTATEQ 58 tramiprosate Alzhemed TM 58 ATPace TM 58 commercialize deforolimus 58 Uvidem 58 DASISION 58 NPC 1C 58 OncoVex 58 THALOMID 58 Romidepsin 58 NP2 Enkephalin 58 telomerase therapeutic 58 HGS ETR2 58 myoblast therapy 58 EndoTAG TM 58 MAGE A3 ASCI 58 vosaroxin 58 Vitaxin 58 oncological indications 58 randomized Phase IIb 58 ThermoDox R 58 isoform selective 58 Quinamed 58 BiovaxID TM 58 refractory Hodgkin lymphoma 58 Vascular Wrap TM 58 confirmatory Phase III 58 oral methylnaltrexone 58 SinuNase 58 KRN# 58 lymphoid malignancies 58 teduglutide 58 ongoing Phase IIIb 58 Cethrin 58 Velcade bortezomib 58 EVIZON TM 58 lapatinib Tykerb 58 encapsulates siRNAs 58 Clolar ® 58 Phase IIIb study 58 histone deacetylase HDAC inhibitor 58 tremelimumab 58 Taxotere R 58 systemic RNAi therapeutic 58 Amoxicillin PULSYS Phase III 58 pharmacokinetic PK study 58 Cx# [002] 58 Specifid 58 IRX 2 58 Acute Radiation Syndrome ARS 58 Sulonex TM 58 Zenvia Phase III 58 amrubicin 58 PEGylated interferon 58 Advagraf 58 Daclizumab 58 Octreolin 58 GEM OS1 58 Proquin XR 58 Cintredekin Besudotox 58 pediatric acute lymphoblastic 58 Canvaxin 58 ATryn ® 58 SinuNase ™ 58 Kamada AAT 58 nasal calcitonin product 58 BRIM3 58 Actimmune ® 58 thetreatment 58 XL# XL# 58 Fodosine 58 Augment TM 58 DCVax R 58 investigational monoclonal antibody 58 Aurexis 58 Lymphoseek ® 58 Targretin 58 efficacy tolerability 58 Asentar 58 ganaxolone 58 reslizumab 58 Phase IIIb 58 Puricase PEG uricase 58 mertansine 58 Novo TTF 58 STEDESA 58 TroVax ® 58 gefitinib Iressa 58 GALNS 58 dacetuzumab 58 rNAPc2 58 VIAtab TM 58 Prednisporin TM 58 CB2 selective receptor agonist 58 ThermoDox ® clinical 58 modified glutathione analog 58 Ixempra 58 Nexavar sorafenib 58 Virulizin R 58 denosumab oncology 58 Trofex TM 58 torezolid phosphate 58 ZFP Therapeutic 58 Nabi HB Intravenous 58 Rescula 58 Nektar proprietary 58 IMC #B 58 Ereska 58 Mepact 58 XP# XP# 58 Plenaxis TM 58 Theratope 58 incyclinide 58 immunotherapeutic approaches 58 Zelrix 58 SNALP technology 58 Phase 2b clinical 57 IMA# 57 ORENCIA R 57 glufosfamide 57 EOquin 57 FOLFOX6 chemotherapy regimen 57 NEUVENGE 57 GED aPC 57 Bioaccelerate compounds under 57 TLK# 57 Nexavar ® 57 multicenter Phase III 57 Combination REOLYSIN R 57 OvaRex 57 unoprostone isopropyl 57 Neulasta ® 57 NovaBay Aganocide compounds 57 MAA submission 57 T Pred 57 NEUMUNE 57 EVIZON TM squalamine lactate 57 Veronate 57 maribavir 57 Deforolimus 57 AAG geldanamycin analog 57 alfa 2a 57 metastatic castrate resistant 57 forodesine HCl 57 aclidinium bromide 57 Fludara 57 LymphoStat B belimumab 57 Adentri 57 Pafuramidine 57 lymphoma CTCL 57 Neo Bladder Augment 57 investigational humanized monoclonal antibody 57 Phase Ib clinical trials 57 radiation sensitizer 57 EmbraceAC 57 Glufosfamide 57 faropenem 57 TNFerade 57 BRAF inhibitor 57 ZYBRESTAT 57 oral rivaroxaban 57 Reolysin 57 Tavocept 57 targeted radiotherapeutic 57 S1P antibody 57 vismodegib 57 fallopian tube cancers 57 Zometa zoledronic acid 57 IV APAP 57 vemurafenib 57 Trovax 57 TRISENOX 57 HCD# [002] 57 ATryn R 57 gastro intestinal inflammation 57 MEK inhibitors 57 HepeX B 57 PF # [002] 57 phase IIb III 57 Inhalation Solution 57 DR Cysteamine 57 G#DT 57 blood clot dissolver 57 phase IIIb 57 Linjeta TM 57 EDEMA3 trial 57 Exelbine 57 DEEP AF 57 TKM PLK1 57 tubulin inhibitor 57 Gemzar ® 57 Virulizin 57 LidoPAIN SP 57 elotuzumab 57 Tarceva TM 57 CLARITY study 57 thalidomide Thalomid 57 satraplatin Phase 57 Fx #A 57 Cimzia ® certolizumab pegol 57 MIST II 57 paclitaxel Taxol ® 57 investigational hepatitis C 57 ALN VSP 57 Taxotere chemotherapy 57 E2F Decoy 57 Archexin 57 Urocortin 2 57 subcutaneous formulation 57 AQ4N 57 Etubics 57 anticancer compound 57 Triapine R 57 Plenaxis R 57 TheraCIM h R3 57 hypoxia activated prodrug 57 Topical Interferon Alpha 2b 57 Alocrest 57 ToGA 57 MEND CABG II 57 Phase III TRIST 57 recombinant biopharmaceutical 57 Immunotherapeutic 57 Avastin adjuvant 57 SNT MC# 57 Phase 2a clinical trials 57 BST CarGel R 57 colorectal lung 57 ENRICH trial 57 rindopepimut 57 Restanza 57 Bezielle 57 antibody MAb 57 KNS # 57 Icatibant 57 Nexavar tablets 57 Elagolix 57 INS# [001] 57 Tocosol Paclitaxel 57 rhThrombin 57 visilizumab 57 iGVHD 57 bardoxolone 57 TRAIL receptor antibodies 57 multicenter Phase II 57 Onconase 57 metastatic HRPC 57 CD# CEA 57 Safinamide 57 sunitinib malate 57 cMET 57 Marqibo 57 Provenge prostate cancer 57 pancreatic prostate 57 AE# vaccine 57 pertuzumab 57 clinicaltrials 57 Temsirolimus 57 vivo validation 57 Hedgehog agonist 57 OncoVEX GM CSF 57 Phase IIB 57 Solazed ™ 57 NASDAQ PHRM 57 BCG refractory 57 TREANDA 57 PROMACTA 57 DCVax R Brain 57 Trofex ™ 57 solid organ transplantation 57 GATTEX ® 57 ASONEP 57 evaluating tivozanib 57 DOS# 57 class mGluR5 inhibitor 57 Chimigen TM 57 Aplidin 57 Cotara R 57 phase 2a 56 BLOOM DM 56 hypereosinophilic syndrome 56 aflibercept 56 DCVax ® Brain 56 sirtuin modulators 56 Tamibarotene 56 dexanabinol 56 Liprostin 56 sapacitabine CYC# 56 Hepatocellular Carcinoma HCC 56 HDAC Inhibitor 56 MyVax ® 56 tezampanel 56 ZACTIMA 56 huN# DM1 56 ZYBRESTAT fosbretabulin 56 sunitinib Sutent 56 Onrigin 56 recurrent NSCLC 56 Phase Ib clinical 56 Omacetaxine 56 cabozantinib 56 personalized immunotherapy 56 AzaSite TM 56 blinatumomab 56 TAXUS TM 56 regorafenib 56 phase IIa 56 psoriasis rheumatoid arthritis 56 concurrent chemoradiation 56 GAMMAGARD 56 PXD# 56 obatoclax 56 QLT# 56 Prodarsan R 56 Squalamine 56 Catena ® 56 orally administered inhibitor 56 Alequel ™ 56 metastatic GIST 56 gastrointestinal disorders ATI 56 Exherin TM 56 Simulect 56 gastrointestinal GVHD 56 relapsed refractory multiple myeloma 56 rALLy 56 Revlimid lenalidomide 56 randomized Phase 2b 56 Neuvenge 56 Provecta 56 balsalazide tablet 56 mapatumumab 56 CORLUX CORT # 56 randomized discontinuation trial 56 Rotarix ® 56 Onco TCS 56 docetaxel emulsion 56 liposomal formulation 56 RhuDex ® 56 sorafenib Nexavar 56 multicenter Phase 56 therapeutic regimens 56 5 fluorouracil leucovorin 56 compound INCB# 56 romidepsin 56 eprodisate KIACTA TM 56 ORADUR ADHD 56 AP# [003] 56 Pivotal Trial 56 Phase III HEAT 56 Homspera TM 56 Aphthasol R 56 evaluating picoplatin 56 bafetinib 56 picoplatin 56 anti CD# antibodies 56 BLP# Liposome Vaccine 56 R vitespen 56 Brentuximab Vedotin SGN 56 phase IIb study 56 crizotinib PF # 56 BRILINTA 56 pomalidomide 56 CEQ# 56 Voraxaze ™ 56 Afatinib 56 Phase III confirmatory 56 M Vax 56 Triapine 56 RELISTOR ® 56 GATTEX TM 56 dirucotide MBP# 56 XL# XL# XL# XL# 56 Phase 2a clinical 56 oral PTH 56 bicifadine 56 adecatumumab MT# 56 HERmark assay 56 ReN# 56 initiated Phase 1b 56 #D#C# 56 Urocidin TM 56 ATG Fresenius S 56 OraTest 56 Sudhir Agrawal D.Phil 56 pivotal bioequivalence 56 investigational immunotherapy 56 LEUKINE 56 Aerosurf 56 CCR5 mAb 56 BAY #-# 56 GVAX Pancreas Vaccine 56 BioSante licensees 56 AdhTAP 56 Somatuline R Autogel R 56 OMAPRO 56 Sandostatin LAR Depot 56 DPP4 inhibitor 56 oral picoplatin 56 Lenocta 56 arzoxifene 56 phase III isavuconazole 56 GRNVAC1 56 Fludara ® 56 Marketing Authorization Application 56 MoxDuo IR 56 essential thrombocythemia ET 56 CUSTOM III 56 systemic ALCL 56 EndoTAG TM -1 56 commercialize ZYFLO CR 56 huC# DM4 56 iclaprim 56 Valtropin 56 Golimumab 56 cytokine refractory 56 MEK Inhibitor 56 tiapamil 56 mitogen activated ERK kinase 56 Study GL# 56 VALSTAR TM 56 gastrointestinal mucositis 56 multiple myeloma MM 56 Davanat 56 Certican 56 telaprevir VX 56 Femara letrozole 56 rFactor XIII 56 GTC recombinant human 56 motesanib 56 dalbavancin 56 Gleevec Glivec 56 CCX# 56 #CL# 56 mifamurtide 56 gemcitabine chemotherapy 56 immunological diseases 56 refractory indolent non 56 Temodar ® 56 INCB# [002] 56 FOLOTYN 56 ara C 56 OraTest R 56 ITAX 56 cancer immunotherapies 56 GLP toxicology studies 56 otelixizumab 56 AERx iDMS 56 receptor tyrosine kinase inhibitor 56 LibiGel Phase III 56 Voraxaze 56 PCA3 assay 56 YONDELIS R 56 Phase III pivotal 56 ACAPODENE TM 56 PROSTVAC TM 56 rBChE 56 Edwards SAPIEN valve 56 OXi# 56 hepatitis C HCV 56 R#/MEM 56 ritonavir boosted danoprevir 56 Pulminiq 56 cediranib 56 Combidex 56 Hyphanox 56 Delcath PHP System 56 Generx ™ 56 Jevtana 56 favorable pharmacokinetic profile 56 Gendux 56 pharmacokinetic PK 56 IV Busulfex 56 MEPACT 56 TAFA# 56 RH1 56 Pimavanserin 56 IMPACT IMmunotherapy 56 ® bortezomib 56 Zingo TM 56 lorvotuzumab mertansine 56 Zavesca r 56 clinical trials 56 CR# vcMMAE 56 isavuconazole 55 CBLC# 55 SILENOR 55 microsphere therapy 55 Phase III Clinical Trial 55 initiate Phase 1b 55 HepaMate 55 bosutinib 55 zanolimumab 55 Phase IIa clinical 55 MyVax 55 cisplatin gemcitabine 55 nosocomial pneumonia 55 Asentar TM 55 methylnaltrexone 55 TOCOSOL Camptothecin 55 MacuSight 55 BCIRG 55 refractory colorectal cancer 55 Phase IIB clinical 55 successfully commercialize Silenor 55 secondary efficacy endpoints 55 vernakalant oral 55 relapsing multiple sclerosis 55 ACTEMRA TM 55 Zavesca R 55 Protexia ® 55 Gleevec imatinib mesylate 55 LUMINATE 55 omacetaxine mepesuccinate 55 RNAi Therapeutic 55 ZEVALIN ® 55 Vidaza ® 55 galiximab 55 STRIDE PD 55 BrainGate TM 55 L MTP PE 55 torsemide ER 55 Cloretazine R VNP#M 55 recurrent GBM 55 anticancer therapy 55 hormone LHRH antagonist 55 Removab 55 #I TM# 55 Hedgehog antagonist 55 Nanobody 55 Nebido 55 Nabi HB 55 Prostate AdenoCarcinoma Treatment 55 Metastatic Melanoma 55 Benlysta belimumab 55 ganetespib 55 cutaneous T cell 55 NeoLipid R 55 metastatic neuroendocrine tumors 55 ICON7 55 ALN VSP Phase 55 PTK# 55 NADiA ProsVue 55 Phase Ib II 55 erlotinib Tarceva ® 55 HGS# 55 Preotact 55 CALGB # [002] 55 Leukine ® 55 MAXY VII 55 AIR2 Trial 55 sarcoma melanoma 55 satraplatin 55 Tykerb lapatinib 55 VeraTag technology 55 darapladib 55 Nuvion 55 IPLEX 55 BCX# 55 enzastaurin 55 clinical endpoints 55 Telintra 55 abiraterone acetate 55 HspE7 55 multicenter multinational 55 efficacy endpoints 55 ProSavin 55 eTag assays 55 Alequel 55 depsipeptide 55 Auxilium anticipates 55 CTLA4 Ig 55 Arzerra ofatumumab 55 genomic biomarker 55 Ceplene TM 55 iniparib 55 Pancreas Cancer Vaccine 55 Gliadel Wafer 55 phase Ib 55 HuMax CD4 55 GRN# 55 LE DT 55 NEVO ™ 55 dirucotide 55 lorcaserin Phase 55 ADVANCE PD 55 Phase #b/#a trial 55 Xeloda ® 55 midstage studies 55 OFIRMEV 55 TOLAMBA 55 IgG1 monoclonal antibody 55 AZX# 55 entinostat 55 Cinryze ™ 55 Nanobody R 55 Rhucin ® recombinant 55 MAb therapy 55 5 Fluorouracil 55 oral Azacitidine 55 ZEFTERA TM Zevtera TM 55 EDEMA3 55 Phase Ib IIa clinical 55 Advaxis Phase 55 APEX PD 55 Tyzeka Sebivo 55 cangrelor 55 bortezomib Velcade 55 drug ISA# 55 afamelanotide 55 Lenocta TM 55 non nucleoside HCV 55 immuno inflammatory diseases 55 recurrent glioblastoma multiforme 55 MYDICAR 55 confirmatory clinical 55 Microplasmin 55 lomitapide 55 Silenor ® doxepin 55 Gattex 55 endothelin antagonist 55 cetuximab Erbitux R 55 recurrent metastatic ovarian cancer 55 panitumumab Vectibix 55 investigational protease inhibitor 55 Erbitux cetuximab 55 INTERCEPT platelets 55 Xcellerated T Cells 55 EVEREST II 55 riociguat 55 HuCNS SC ® 55 Phase III clinical 55 ENDEAVOR IV 55 postapproval 55 JAK2 Inhibitor 55 PFO migraine 55 Synavive 55 Ophena 55 TransVax ™ 55 generic Copaxone 55 Motesanib 55 CIMZIA TM 55 Phase III Pivotal 55 CRLX# 55 ANYARA 55 Preos 55 Fabry Disease 55 VNP#M 55 metastatic castration resistant 55 ORBIT II 55 ZK EPO 55 oral taxane 55 Onrigin TM 55 pafuramidine 55 DCVax R Prostate 55 Fablyn 55 pemetrexed Alimta 55 PRIMO CABG2 55 Argatroban 55 Bayer Onyx 55 phase IIb trial 55 Orapred ODT 55 relapsed leukemia 55 cilengitide 55 oral FTY# 55 miconazole MBT 55 TRANSDUR Sufentanil 55 TÎ ² 4 55 GRN#L 55 candidate AQ4N 55 Alzhemed TM 55 Sphingomab TM 55 Amigal 55 CDK cyclin dependent 55 BARACLUDE R 55 bevacizumab Avastin ® 55 pharmacodynamic markers 55 elacytarabine 55 Apoptone 55 hESC derived RPE cells 55 Phase #/#a 55 rThrombin 55 Fortical R 55 monoclonal antibody conjugated 55 sapacitabine 55 etanercept Enbrel 55 Zenapax 55 LHRH antagonists 55 therapeutic monoclonal antibody 55 refractory angina 55 Alnylam #x# 55 TransVax TM 55 Fibrillex TM 55 number NCT# ClinicalTrials.gov 55 Severe Sepsis 55 5 lipoxygenase inhibitor 55 chronic myocardial ischemia